多发性硬化症治疗药物研究进展  

Drug therapy of multiple sclerosis: research advances

作　　者：张菲菲[1] 李静[1] 

机构地区：[1]中国科学院上海药物研究所,上海201203

出　　处：《国际药学研究杂志》2014年第3期296-300,341,共6页Journal of International Pharmaceutical Research

基　　金：国家自然科学基金资助项目(81202341)

摘　　要：多发性硬化症(multiple sclerosis,MS)是一类发生在人中枢神经系统的自身免疫性脱髓鞘疾病。目前无彻底治愈的方法,只是利用药物减缓、控制病情的进展。已经上市的临床药物主要针对免疫系统,靶向中枢神经系统的新治疗策略也越来越受到重视。针对中枢神经系统的神经保护药物也已进入临床试验阶段,在未来几年可能用于提高神经元的功能和存活。本文主要介绍已上市的MS治疗药物、给药方式、作用机制、安全性和有效性,并简要介绍正在研发的新药。Muhiple sclerosis（MS） is an autoimmune disease characterized by the immune-mediated demyelination of the cen- tral nervous system （CNS）. There are still no disease-modifying therapeutics to cure MS per se, all patients need drugs to control their diseases. Most drugs in clinic target the immune system. New therapeutic strategies have evolved that specifically target the neurode- generative aspect of MS. Remyelinating agents are actively under investigation, and may yield novel strategies to increase neuronal functionality and survival in the coming years. In this review, we mainly describe the administration, mechanism of action, safety and efficacy of dugs currently approved for MS therapy. We also briefly introduce the new drugs for the treatment of MS currently under in- vestigation.

关 键 词：多发性硬化症 药物治疗 神经保护 

分 类 号：R744.51[医药卫生—神经病学与精神病学]